Apellis Pharmaceuticals ( (APLS) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Apellis Pharmaceuticals’ stock is on the rise following the FDA’s approval of its drug, Empaveli. This regulatory success has prompted analysts to revise their price targets upwards, with Scotiabank and Citi highlighting the drug’s market potential and expanded label approval. Despite a slower commercial ramp and missing Q2 revenue expectations, the company’s strong prospects in treating C3 glomerulopathy and other conditions have bolstered investor confidence.
More about Apellis Pharmaceuticals
YTD Price Performance: -42.70%
Average Trading Volume: 2,485,755
Technical Sentiment Signal: Sell
Current Market Cap: $2.38B
For further insights into APLS stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.